| 项目 | 工作内容 公司2024年存在关联交易未履行必要的审 | | --- | --- | | | 议程序及信息披露程序情形，保荐机构在 | | | 获悉此事后对公司进行了专项现场检查。 | | （3）现场检查发现的主要问题及整改情况 | 公司已履行关联交易审议程序，追认上述 | | | 关联交易事项并补充公告上述关联交易事 | | | 项。 | | 6.发表专项意见情况 | | | （1）发表专项意见次数 | 9 | | （2）发表非同意意见所涉问题及结论意见 | 不适用 | | 7.向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 0 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8.关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 无 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | 无 | | （1）培训次数 | 1次 | | （2）培训日期 | 20 ...

国泰海通证券股份有限公司 关于实朴检测技术（上海）股份有限公司 2024 年度持续督导工作现场检查报告 | 保荐人名称：国泰海通证券股份有限公司 被保荐公司简称：实朴检测 | | --- | | （以下简称"国泰海通"或"保荐人"） | | 保荐代表人姓名：曾军 联系电话：021-23180000 | | 保荐代表人姓名：石冰洁 联系电话：021-23180000 | | 现场检查人员姓名：石冰洁 | | 现场检查对应期间：2024 年 月 日-2024 年 月 日 1 1 12 31 | | 现场检查时间：2025 年 4 月 23 日-2025 年 4 月 24 日 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段： | | （2）察看上市公司的主要经营场所； | | （3）查阅公司信息披露文件； | | （4）查阅公司相关三会文件，包括会议通知、议案、表决票、会议记录、决议等； | | （5）查阅并核查公司章程、三会规则及各项公司治理制度的具体内容及执行情况。 | | 1.公司章程和公司治理制度是否完备、合规 √ | | 2.公司章程和股东大会、董事会 ...

国泰海通证券股份有限公司 关于实朴检测技术（上海）股份有限公司 2024年度日常关联交易确认和2025年度日常关联交易预计 的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为实 朴检测技术（上海）股份有限公司（以下简称"实朴检测"或"公司"）持续督导 的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公 司自律监管指引第 13 号——保荐业务》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所创业板上市公司自律监管指引——第 2 号创业板上市公司规 范运作》等相关法律、法规和规范性文件的规定，对实朴检测 2024 年度日常关 联交易确认及 2025 年度日常关联交易预计的事项进行了专项核查，核查情况与 意见如下： 一、日常关联交易基本情况 （一）日常关联交易概述 公司因日常经营和业务发展需要，结合公司实际情况，预计 2025 年度将与 关联方四川多克特生态环境技术有限公司（以下简称 "四川多克特"）、 浙江浙 海环保科技有限公司（以下简称 "浙江浙海"）、北京实农技术服务有限公司 （以下简称 "北京实农"）、上海成橙信息科技有限公司（以下简称 "上海成 橙"） ...

国泰海通证券股份有限公司 关于实朴检测技术（上海）股份有限公司 2024 年度内部控制自我评价报告的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通证券"或"保荐机构"）作为 实朴检测技术（上海）股份有限公司（以下简称"实朴检测"或"公司"）首次公开 发行股票并在创业板上市的持续督导保荐机构，根据《证券发行上市保荐业务 管理办法》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《企 业内部控制基本规范》等法律、法规和规范性文件的要求，对《实朴检测技术 （上海）股份有限公司 2024 年度内部控制自我评价报告》进行了核查，具体情 况如下： 一、内部控制评价的范围 公司根据风险导向原则确定评价范围。评价范围的主要单位包括公司及重 要控股公司。纳入评价范围单位资产总额占公司合并财务报表资产总额的 100%， 营业收入合计占公司合并财务报表营业收入总额的 100%。业务事项包含内部环 境、风险评估、控制活动、信息与沟通、内部监督等内控五个主要要素和高风 险领域。 二、内部控制评价工作依据及内部控制缺陷认定标准 内部控制缺陷 ...

证券代码：301228 证券简称：实朴检测 公告编号：2025-036 实朴检测技术（上海）股份有限公司 关于回购股份（第二期）的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 （一）公司回购股份的时间、回购股份的数量、回购股份的方式、集中竞价交易 的委托价格、委托时段等符合《深圳证券交易所上市公司自律监管指引第9号——回 购股份》的相关规定及公司《回购报告书（第二期）》内容，具体如下： 实朴检测技术(上海)股份有限公司（（以下简称"公司"）于2025年1月8日召开的 第二届董事会第十六次会议审议通过了《关于公司回购股份方案（第二期）的议案》，同 意公司使用自有资金以集中竞价交易方式进行股份回购，该部分回购的股份拟用于实 施员工持股计划或股权激励。本次回购总金额不低于人民币2,000万元且不超过人民 币4,000万元（均包含本数），回购价格不超过人民币22.46元/股（含）。本次回购股 份的实施期限为自董事会审议通过本回购股份方案之日起12个月内。具体内容详见公 司分别于2025年1月8日、2025年1月13日在巨潮资讯网（（http://www.c ...

Core Viewpoint - The company aims to standardize and systematize testing processes in the industry, promoting a more regulated environment and enhancing public health through comprehensive testing services [2][7]. Group 1: Company Background and Development - Established in 2008, the company started with soil and groundwater testing and has since expanded to over 7,000 testing parameters across various fields including solid waste, air, water, and dioxin testing [2][5]. - The founder, Yang Jin, has nearly 20 years of experience in the field, having previously worked in both public health and foreign environmental testing institutions [3][4]. - The company has participated in the establishment of 31 national standards for soil and groundwater testing, with 21 already implemented by the end of 2024 [4]. Group 2: Business Expansion and Strategy - After going public in 2022, the company adopted a "dual-wheel drive" strategy, expanding its testing services to include food and agriculture, thus creating a comprehensive third-party testing service system [5][6]. - The company is exploring automation and intelligent transformation in testing processes, including a partnership with Qiteng Robotics to develop intelligent testing robots [6][8]. Group 3: Social Responsibility and Community Engagement - The company actively engages in social responsibility, providing free water quality testing services during natural disasters, demonstrating a commitment to public health and safety [7][8]. - The founder emphasizes the importance of technology in benefiting society, linking soil and groundwater safety to public health [7][8]. Group 4: Future Outlook - The company anticipates growth in the testing and inspection industry due to ongoing global economic development and technological advancements, planning to increase investment and acquisition efforts [8]. - There is a focus on leveraging accumulated data to create value and enhance the maturity of the testing industry, ensuring sustainable development and addressing societal challenges [8].

Group 1 - Shenjian Co., Ltd. reported a net profit of 33.65 million yuan for 2024, a year-on-year increase of 32.29%, with a proposed cash dividend of 0.5 yuan per 10 shares [1] - Jingce Electronics experienced a net loss of 97.60 million yuan in 2024, transitioning from profit to loss, despite a revenue increase of 5.59% to 2.565 billion yuan [1] - Jingwei Co., Ltd. reported a net profit of 35.54 million yuan for 2024, a decrease of 36.76%, with a proposed cash dividend of 1.00 yuan per 10 shares [1][2] Group 2 - Minsheng Health achieved a net profit of 91.83 million yuan in 2024, a year-on-year increase of 7.24%, with a proposed cash dividend of 1.00 yuan per 10 shares [2] - Zhongshe Co., Ltd. reported a net profit of 10.16 million yuan for 2024, a decline of 76.24%, with a proposed cash dividend of 0.2 yuan per 10 shares [3] - Keyuan Smart reported a net profit of 252 million yuan for 2024, a year-on-year increase of 56.64%, with a proposed cash dividend of 0.4 yuan per 10 shares [4] Group 3 - Beilu Pharmaceutical reported a net profit of 14.54 million yuan for Q1 2025, a year-on-year increase of 26.13%, with revenue of 283 million yuan [5] - Wangsu Technology achieved a net profit of 192 million yuan for Q1 2025, a year-on-year increase of 38.54%, with revenue of 1.235 billion yuan [6] - Keyuan Pharmaceutical reported a net profit of 23.08 million yuan for Q1 2025, a year-on-year increase of 7.25%, despite a revenue decline of 23.98% [7] Group 4 - Guangting Information reported a net profit of 24.03 million yuan for Q1 2025, turning from loss to profit, with revenue of 134 million yuan [9] - Zhaori Technology reported a net loss of 1.23 million yuan for Q1 2025, with revenue of 35.23 million yuan [11] - Huakai Yibai reported a net loss of 15.09 million yuan for Q1 2025, despite revenue growth of 35.08% to 2.292 billion yuan [13] Group 5 - Xinhongye reported a net profit of 34.43 million yuan for Q1 2025, a year-on-year increase of 20.43%, with revenue of 755 million yuan [15] - Huning Co., Ltd. reported a net profit of 3.61 million yuan for Q1 2025, a year-on-year decrease of 45.68%, with revenue of 64.51 million yuan [16] - Camel Co., Ltd. reported a net profit of 237 million yuan for Q1 2025, a year-on-year increase of 51.89%, with revenue of 4.136 billion yuan [17] Group 6 - Hengtong Co., Ltd. reported a net profit of 42.55 million yuan for Q1 2025, a year-on-year increase of 51.62%, with revenue of 313 million yuan [19] - Changqing Technology reported a net profit of 35.38 million yuan for Q1 2025, a year-on-year decrease of 23.80%, with revenue of 246 million yuan [21] - Libaba Co., Ltd. reported a net profit of 34.72 million yuan for Q1 2025, a year-on-year increase of 9.91%, with revenue of 419 million yuan [22] Group 7 - Shouxiangu reported a net profit of 58.37 million yuan for Q1 2025, a year-on-year decrease of 24.32%, with revenue of 171 million yuan [24] - Bojun Technology announced a stock issuance application accepted by the Shenzhen Stock Exchange [24] - Dayou Energy announced the full resumption of production at its Gengcun coal mine, with an annual production capacity of 3.6 million tons [25] Group 8 - Deyang Co., Ltd. successfully acquired land use rights for industrial land in Ningbo for 45.80 million yuan [27] - Tianyu Pharmaceutical's subsidiary received a drug registration certificate for an injectable product [29] - Xingwang Yuda signed a strategic cooperation agreement with the Jilin Province Bionic Robot Innovation Center [30] Group 9 - Lifang Pharmaceutical received approval for clinical trials of a new drug [32] - Zai Sheng Technology reported a net profit of 33.56 million yuan for Q1 2025, a year-on-year increase of 3.69%, with revenue of 324 million yuan [34] - Jinxin Technology reported a net profit of 319,920 yuan for Q1 2025, turning from loss to profit, with revenue of 563 million yuan [36] Group 10 - Huayin Electric reported a net profit of 75.67 million yuan for Q1 2025, a year-on-year increase of 894.61%, with revenue of 2.307 billion yuan [37] - Xinghua Co., Ltd. reported a net loss of 95.51 million yuan for Q1 2025, with revenue of 840 million yuan [38] - Heren Technology reported a net loss of 384,410 yuan for Q1 2025, with revenue of 78.40 million yuan [40] Group 11 - Fenda Technology reported a net profit of 40.45 million yuan for Q1 2025, a year-on-year increase of 84.07%, with revenue of 760 million yuan [41] - Tongda Co., Ltd. reported a net profit of 25.49 million yuan for 2024, a year-on-year decrease of 69.15%, with revenue of 6.201 billion yuan [43] - Zhonghe Holdings reported a net profit of 283 million yuan for 2024, a year-on-year decrease of 54.69%, with a proposed cash dividend of 0.3 yuan per 10 shares [44] Group 12 - Jiantou Energy reported a net profit of 531 million yuan for 2024, a year-on-year increase of 181.59%, with a proposed cash dividend of 1.3 yuan per 10 shares [44] - Guanghua Technology reported a net loss of 205 million yuan for 2024, with revenue of 2.589 billion yuan [45] - Huajin Technology reported a net profit of 29.26 billion yuan for 2024, a year-on-year increase of 8.1%, with a proposed cash dividend of 9 yuan per 10 shares [46] Group 13 - Yingke Medical reported a net profit of 1.465 billion yuan for 2024, a year-on-year increase of 282.63%, with a proposed cash dividend of 1.00 yuan per 10 shares [46] - Solar Energy reported a net profit of 1.225 billion yuan for 2024, a year-on-year decrease of 22.38%, with a proposed cash dividend of 0.56 yuan per 10 shares [46] - Dongfang Electric reported a net profit of 318 million yuan for 2024, a year-on-year decrease of 50.62%, with a proposed cash dividend of 0.32 yuan per 10 shares [47] Group 14 - Tianneng Heavy Industry reported a net loss of 262 million yuan for 2024, with revenue of 3.273 billion yuan [48] - Gangyan High-tech reported a net profit of 249 million yuan for 2024, a year-on-year decrease of 22.08%, with a proposed cash dividend of 1.00 yuan per 10 shares [48] - Shihua Machinery reported a net profit of 96.88 million yuan for 2024, a year-on-year increase of 5.35%, with revenue of 8.037 billion yuan [49] Group 15 - Gongtong Pharmaceutical reported a net loss of 27.59 million yuan for 2024, with revenue of 537 million yuan [51] - Zhongjing Electronics reported a net loss of 87.43 million yuan for 2024, with revenue of 2.932 billion yuan [53] - Yudai Development reported a net loss of 114 million yuan for 2024, with revenue of 388 million yuan [55] Group 16 - Zhenhua Technology reported a net profit of 970 million yuan for 2024, a year-on-year decrease of 63.83%, with a proposed cash dividend of 1.8 yuan per 10 shares [56] - Jierong Technology reported a net loss of 298 million yuan for 2024, with revenue of 1.357 billion yuan [58] - Changgao Electric New reported a net profit of 252 million yuan for 2024, a year-on-year increase of 45.66%, with a proposed cash dividend of 0.8 yuan per 10 shares [60] Group 17 - Shibao Detection announced a plan to acquire 81% of Zhonghuan Lianshu for 52.65 million yuan [61] - Jiangsu Boyun announced a plan to reduce its shareholding by up to 3% [62] - Jingfeng Mingyuan announced a plan to acquire 100% of Yichong Technology for 3.283 billion yuan [63]

2024 年度独立董事述职报告 作为实朴检测技术（上海）股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国 证券法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 等法律法规以及《实朴检测技术（上海）股份有限公司章程》（以下简称"《公 司章程》"）、《实朴检测技术（上海）股份有限公司独立董事工作制度》等相 关规定，本人在 2024 年度工作忠实履行独立董事职责，对公司的生产经营和业 务发展提出了合理的建议，充分发挥了独立董事作用，维护了公司股东，尤其是 中小股东的合法权益。现将 2024 年度的职情况报告如下： 一、基本情况 本人李金桂，公司独立董事，男，中国国籍，1976 年 6 月生，无境外永久 居留权，本科学历，中国注册会计师，高级会计师职称。2009 年 7 月至 2016 年 4 月，任公证天业会计师事务所(特殊普通合伙)苏州分所项目经理；2016 年 4 月 至 2017 年 3 月，任苏州东菱振动试验仪器有限公司副总经理；2017 年 3 月至 2022 年 10 月，任大信会计师事务所(特殊普通合伙)江苏分所高 ...

实朴检测技术（上海）股份有限公司 2024 年度独立董事述职报告 作为实朴检测技术（上海）股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国 证券法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 等法律法规以及《实朴检测技术（上海）股份有限公司章程》（以下简称"《公 司章程》"）《实朴检测技术（上海）股份有限公司独立董事工作制度》等相关 规定，本人在 2024 年度工作中能够诚实、勤勉、独立地履行职责，积极出席相 关会议，认真审议董事会各项议案，切实维护了公司和股东的利益，充分发挥了 独立董事的作用。现将履职情况汇报如下： 一、基本情况 本人李浩，公司独立董事，男，中国国籍，1976 年 3 月生，无境外永久居 留权，博士后，教授。1999 年 7 月至 2003 年 6 月任中科院上海有机化学研究所 实习员，2010 年 1 月至 2011 年 11 月任中科院上海药物研究所副研究员，2011 年 12 月至今任华东理工大学教授，2022 年 11 月至今任公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》 ...

二〇二四年四月 实朴检测技术（上海）股份有限公司 章程 实朴检测技术（上海）股份有限公司 章 程 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | 第一节 | 股份发行 2 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 5 | | 第四章 | 股东和股东大会 6 | | 第一节 | 股东 6 | | 第二节 | 股东大会的一般规定 8 | | 第三节 | 股东大会的召集 11 | | 第四节 | 股东大会的提案与通知 12 | | 第五节 | 股东大会的召开 14 | | 第六节 | 股东大会的表决和决议 17 | | 第五章 | 董事会 20 | | 第一节 | 董事 20 | | 第二节 | 董事会 23 | | 第六章 | 总经理及其他高级管理人员 28 | | 第七章 | 监事会 30 | | 第一节 | 监事 30 | | 第二节 | 监事会 30 | | 第八章 | 财务会计制度、利润分配和审计 32 | | --- | --- | | 第一节 | 财务会计制度 32 | | 第二节 | 内部 ...